Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSB-50
- Development stage
- Preclinical
- Lead developer
- Dalhousie University
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
DSB-50 is a synthetic, C-ring modified prodigiosene derivative developed as a potential anti-leukemia agent. It is a structural analog of the naturally occurring compound prodigiosin, designed to maintain anti-cancer potency while reducing the characteristic toxicity of the parent molecule. DSB-50 has demonstrated in vitro activity against various leukemia cell lines, including K562, CCRF-CEM, and MOLT-4, and has shown moderate cytotoxic activity in vivo within zebrafish xenograft models of chronic myelogenous leukemia (CML). The compound was synthesized and evaluated by researchers at Dalhousie University and the IWK Health Centre.
- Other names
- C-ring modified prodigiosene
Beyond the preview
Go deeper on DSB-50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSB-50.